Saccharomyces boulardii can ameliorate DSS-induced colitis in mice by inhibiting the activation of nuclear factor kappa-B (NF-κB) signaling pathway and inhibiting the release of pro-inflammatory cytokines (Gao et al., 2021). Here, NFKB1 is linked to colitis.